Skip to main content


Our Mission

  • High standards of research and education focusing on the evidence-based, personalised and individualised approaches in neuropsychiatry and incorporating trends in clinical innovations and new AI-based technologies.
  • Meeting of basic and clinical neurosciences for better quality of care for mental, behavioural and neurological disorders.
  • International collaboration initiatives, fostering mentorship and integration into the global professional community.


Our Goals

  • Goal 1. To develop an effective team of collaborators, with human resources as a key priority.

    Growing our network of collaboration worldwide in the manner of cultivating connections within healthy brain.

  • Goal 2. To speak a common scientific idiom, through mutual agreements on the formulation of hypotheses and obtaining evidence-based expertise.

    Dialogue between basic and clinical neurosciences leading towards better treatment outcomes.

  • Goal 3. To manage meaningful projects in the domains of research & development, and clinical guidelines in neuropsychiatry using innovative technologies.

    Teamwork focusing on research achievements, professional education, and improved quality of life of patients.


Education

  • Hybrid & Russian/English bilingual format.
  • Professional events, certified CME courses and on-line ICERN WEB-library of neuropsychiatry.
  • Development of the MSc programme in Clinical Neurosciences (EU & national matched standards).

Science

  • Research projects.
  • National and international grants.
  • Peer-review publications.

Clinical Practice

  • Person-centered and evidence-based approach.
  • Individualised treatment strategies.
  • Innovative technologies.

Our Field of Expertise

  • COVID-19-associated psychiatric and neurological complications (outpatients, in-patients with severe illness in COVID-hospitals, rare clinical cases, COVID-associated olfactory disorders).
  • Mental health, social and psychological well-being of the population during COVID-19 pandemic and associated lockdowns and in the context of vulnerable populations (general aged population, students, patients with cardiovascular disorders, health professionals, etc.).
  • Psycholinguistics and neurolinguistics of socially significant mental disorders (depression, schizophrenia, dementia, etc.).
  • Thought, language and communication disorder and social disadjustment in patients with schizophrenia spectrum disorders (i.e. cognitive endophenotypes of schizophrenia, and studies of patients and first-degree relatives).
  • Neurocognition, social/emotional intelligence and ML/AI-based neural networks discovering facial mimic and speech patterns in schizophrenia spectrum and affective disorders.
  • Motor dysfunction, verbal fluency decline, disrupted embodied cognition and negative symptoms in schizophrenia spectrum disorders.
  • Intensive action language treatment in psychiatric and neurological disorders.
  • Machine learning and artificial intelligence: Big data for the linguistics of mental disorders.
  • Epidemiology of mental disorders, stress-related environmental conditions, public health, mental health services, children & adolescent mental health, Memory clinics and psychogeriatric services.
  • Evidence-based and person-centered individualized psychoharmacotherapy of mental disorders.
  • Genetic and psychoneuroimmunological biomarkers of mental and behavioral disorders, psychopharmacogenetics and clinical trials of novel molecules.
  • Hereditary neurodegenerative diseases (Huntington’s disease, Alzheimer’s disease, Parkinson’s disease, orphan neurological diseases).
  • Virtual, and augmented reality and biofeedback techniques as evidence-based novel approaches to treatment and interdisciplinary rehabilitation of patients with mental, behavioural and neurological disorders.
  • Women’s mental health, prevention of violence against women, and mental health in immigrant populations.

Methods

  • Clinical interview & Semi-structured Interviews (i.e. Diagnostic Interview for Psychoses – DIP).
  • Pathopsychological investigation & Rating scales assessments.
  • Psycholinguistic method (i.e. NLP, content analysis, narrative analysis, Neural Networks, action-language approach).
  • Patients’ creative art (i.e. painting, performing, dancing).
  • Implementation of advanced technologies and equipment in the fields of:

    • Brain imaging (i.e., MRI, fMRI, PET, CT).
    • Neurophysiology & physiology (i.e., EEG, EMG, eye-tracking, pulse tracking, breath sensors, thermography cameras).
    • Novel treatment approaches (i.e., rTMS, VR/AR – ReViSide devices, day light therapy, RunWalkTalk project, advanced approaches in verbal psychotherapy and psychosocial rehabilitation).